Novartis gets FDA nod for Cosentyx IV formulation for rheumatic diseases
The FDA has cleared Cosentyx as the first IV formulation interleukin-17A antagonist for adults with psoriatic arthritis, ankylosing…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Oct 23
The FDA has cleared Cosentyx as the first IV formulation interleukin-17A antagonist for adults with psoriatic arthritis, ankylosing…
09 Oct 23
The Type II extension of indication application seeks approval for Rybrevant combo as a first-line treatment of NSCLC…
09 Oct 23
Noul Co., Ltd., (376930.KR), an Artificial Intelligence (AI) based blood and cancer diagnostic platform company, has newly introduced…
09 Oct 23
TOFIDENCE is the first monoclonal antibody drug researched, developed, and manufactured by a Chinese pharmaceutical company to receive…
09 Oct 23
When designated as an orphan drug, there are incentives such as tax credits for clinical development costs and…
06 Oct 23
The acquisition will strengthen Kyowa Kirin’s portfolio with several HSC gene therapies targeting serious diseases, maximise the value…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Oct 23
The deal includes Mitokinin's lead asset, a selective PINK1 activator, which is designed to mitigate mitochondrial dysfunction factor…
06 Oct 23
Under the agreement, Biovectra will use Acuitas’ LNP technology platform on a non-exclusive basis to manufacture the mRNA-based…
06 Oct 23
The acquisition will allow Sharp to provide a comprehensive, fully integrated solution for small-to-medium-scale sterile injectable services within…
06 Oct 23
In the second year of the meat sector’s pioneering data collection and reporting on five key focus areas…